Suppliers / Curia France Sas

Curia France Sas

France Updated 9 July 2026

The public registers hold a second record for Curia France Sas. The fuller profile, with 116 active US DMFs and 8 valid CEPs, is at Curia. Figures on this page cover only this record.

Curia France Sas is an API manufacturer based in France. It holds 2 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 3 March 2022 as VAI.

2
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 3 March 2022 VAI US FDA
  • 8 October 2021 VAI US FDA
  • 17 January 2019 VAI US FDA
  • 18 November 2014 NAI US FDA
  • 13 November 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
France, France 3006257961
France, France 3009615607

What they file, and where

Molecule Regulators Docs
Aztreonam US FDA 2

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. Curia France Sas comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 3 March 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability